	US 11,987,604 B2
	Fusion-proteins based on human ferritin and protease-cleavable peptides and their use as chemotherapeutics carriers
Aldo Braca, Latina (IT)
Assigned to THENA BIOTECH S.R.L., Latina (IT)
Appl. No. 16/761,303
Filed by THENA BIOTECH S.R.L., Latina (IT)
PCT Filed Nov. 5, 2018, PCT No. PCT/IB2018/058655 § 371(c)(1), (2) Date May 4, 2020, PCT Pub. No. WO2019/087155, PCT Pub. Date May 9, 2019.
Claims priority of application No. 102017000116184 (IT), filed on Nov. 6, 2017.
Prior Publication US 2021/0403515 A1, Dec. 30, 2021
Int. Cl. C07K 14/47 (2006.01); A61K 9/51 (2006.01); A61K 47/64 (2017.01); A61K 47/69 (2017.01); A61P 35/00 (2006.01)

CPC C07K 14/47 (2013.01) [A61K 9/51 (2013.01); A61K 47/64 (2017.08); A61K 47/6925 (2017.08); A61P 35/00 (2018.01); C07K 2319/31 (2013.01); C07K 2319/33 (2013.01); C07K 2319/50 (2013.01)]

13 Claims

1. A fusion protein comprising at least three domains, wherein:

(a) a first domain comprises the amino acid sequence of the heavy chain of native human ferritin or a variant thereof having at least 90% identity with the amino acid sequence of the heavy chain of native human ferritin (SEQ ID NO:1);

(b) a second domain comprises the amino acid sequence of a matrix metalloproteinase (MMP) cleavage site; and

(c) a third amino-terminal domain consists of the amino acid sequence of a polypeptide of at least 20 amino acid residues and which consists essentially of proline, serine and alanine and at least one negatively charged residue selected from glutamate or aspartate (PASE),

wherein the second domain comprises the amino acid sequence of a matrix metalloproteinase (MMP) cleavage site selected from the group consisting of MMP2, MMP3, MMP7, and MMP9.